Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?
Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?
复制标题
DOI：
10.3233/jpd-160798
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Brundin P
中科院分区：
文献类型：
--
作者：
Barker RA;Parmar M;Kirkeby A;Björklund A;Thompson L;Brundin P
最近有消息称即将进行一项使用孤雌干细胞作为供体组织来源的帕金森病临床细胞移植试验，这给患者群体带来了希望，并引发了研究界的讨论。根据一项关于帕金森病干细胞疗法转化的全球合作倡议进行的讨论，我们确定了一系列关键问题，我们认为在针对这种疾病的每一次临床干细胞移植试验之前都应该解决这些问题。在本文中，我们首先提供了帕金森病细胞疗法的简短历史，并简要描述了用于任何患者试验的人类干细胞衍生的多巴胺神经元的当前最新技术。以此背景信息为基础，我们然后讨论与即将进行的治疗试验相关的每个关键问题，并严格评估孤雌干细胞技术临床转化治疗帕金森病的时机是否成熟。
Recent news of an impending clinical cell transplantation trial in Parkinson’s disease using parthenogenetic stem cells as a source of donor tissue have raised hopes in the patient community and sparked discussion in the research community. Based on discussions held by a global collaborative initiative on translation of stem cell therapy in Parkinson’s disease, we have identified a set of key questions that we believe should be addressed ahead of every clinical stem cell-based transplantation trial in this disorder. In this article, we first provide a short history of cell therapy in Parkinson’s disease and briefly describe the current state-of-art regarding human stem cell-derived dopamine neurons for use in any patient trial. With this background information as a foundation, we then discuss each of the key questions in relation to the upcoming therapeutic trial and critically assess if the time is ripe for clinical translation of parthenogenetic stem cell technology in Parkinson’s disease.